Postpartum depression

What it is

Postpartum depression (PPD) is a clinical mood disorder affecting approximately 1 in 7 people — about 10–15% of mothers, with some estimates reaching 20% under broader definitions — that develops after childbirth and does not resolve without support or treatment. Also called perinatal depression, PPD is formally classified in the DSM-5-TR as a major depressive episode with peripartum onset, beginning during pregnancy or within 4 weeks of delivery, though clinically it is recognized throughout the full first postpartum year.

PPD is distinct from the baby blues, a brief, self-limiting period of tearfulness, mood swings, and emotional fragility that affects up to 80% of new mothers in the first week after delivery and resolves on its own within 10–14 days. PPD is more severe, lasts longer, and significantly impairs a parent's ability to function and bond with their baby. Despite affecting roughly 20,000–25,000 Canadian mothers annually (based on approximately 370,000 births per year), PPD remains significantly underdiagnosed — up to 50% of cases go undetected, according to StatPearls — because stigma, the social expectation of new-parent happiness, and overlap with normal postnatal exhaustion all make disclosure difficult.

PPD can also affect fathers and non-birthing parents. Paternal PPD affects approximately 8–10% of new fathers, typically peaking between 3 and 6 months postpartum, and is even less likely to be screened for or treated.

Causes and mechanism

PPD is multifactorial, involving hormonal shifts, biological vulnerabilities, and psychosocial stressors.

Hormonal trigger: Within 24–48 hours of delivery, estrogen and progesterone fall from their highest levels of pregnancy to their lowest. This precipitous withdrawal is thought to destabilize serotonin and dopamine signalling in individuals with a biological sensitivity to hormonal fluctuation — a mechanism reviewed in detail by Schiller et al. (2015, CNS Spectrums). Separately, postpartum thyroiditis occurs in approximately 5–10% of postpartum women and can produce a hypothyroid phase that mimics or worsens depression; thyroid function testing is therefore part of a standard PPD workup.

Biological risk factors:

• Personal history of depression, anxiety, or premenstrual dysphoric disorder (PMDD)
• Prior episode of PPD (recurrence risk is substantially elevated)
• Family history of mood disorders
• Fragmented or severely disrupted sleep

Psychosocial risk factors:

• Limited partner or social support
• Stressful life events during or after pregnancy
• Relationship difficulties or financial stress
• Unplanned pregnancy
• History of trauma or abuse
• Difficulties with breastfeeding or infant care

Symptoms and diagnosis

Symptoms that persist beyond 2 weeks after delivery and exceed the normal fatigue of new parenthood warrant clinical assessment. Common features include persistent low mood or emptiness, excessive crying, loss of interest in previously enjoyed activities, overwhelming fatigue, difficulty bonding with the baby, feelings of worthlessness or guilt, anxiety, irritability, appetite and sleep disturbances beyond what the infant's schedule imposes, and withdrawal from family and friends. In severe cases, intrusive thoughts of harming oneself or the baby require immediate professional intervention.

Diagnostic approach:

Tool	Purpose	Threshold
Edinburgh Postnatal Depression Scale (EPDS)	Validated 10-item screening questionnaire; used routinely in Canadian primary care and obstetric settings	Score ≥ 13 warrants clinical assessment
Clinical interview	Assess symptom duration, severity, and functional impact	—
TSH (thyroid-stimulating hormone)	Rule out postpartum thyroiditis as a contributing cause	—
CBC and iron studies	Rule out postpartum anaemia from delivery blood loss	—

The EPDS is the most widely used screening tool in Canada; the Society of Obstetricians and Gynaecologists of Canada (SOGC) supports routine perinatal mental health screening at prenatal and postnatal visits.

Treatment options

PPD is highly treatable, and early intervention improves outcomes for both parent and infant.

Psychotherapy: Cognitive behavioural therapy (CBT) is the most evidence-supported psychological treatment for PPD, targeting negative thought patterns and behavioural contributors to depression. Interpersonal therapy (IPT), which addresses role transitions and relationship changes around new parenthood, is also effective. Structured peer support groups reduce isolation and complement formal therapy.

Antidepressant medication: SSRIs are first-line pharmacological treatment. Sertraline and paroxetine have the lowest transfer into breast milk and are generally preferred for breastfeeding women; fluoxetine is also used. SNRIs are effective alternatives when SSRIs are not tolerated. Combined therapy — medication plus psychotherapy — is more effective than either alone for moderate to severe PPD. Canadian prescribers follow guidance from the SOGC and the Canadian Psychiatric Association when selecting agents during lactation.

Hormonal treatments: Brexanolone (Zulresso), a synthetic form of allopregnanolone (a neurosteroid derived from progesterone), is approved in the United States as a 60-hour IV infusion for PPD and can produce rapid relief within 2–3 days. An oral formulation, zuranolone, has also received US approval. As of 2025, neither has received Health Canada approval for PPD; Canadian patients seeking these options should discuss clinical trial access or cross-border considerations with their physician.

Supportive measures: Maximizing sleep where possible, practical support from family or community, and treating postpartum thyroiditis if identified all contribute to recovery.

When to see a clinician in Canada

Seek assessment from a family physician, midwife, or obstetrician as soon as possible if, after childbirth, you or someone you know experiences:

• Low mood, persistent crying, or hopelessness lasting more than 2 weeks
• Difficulty caring for the baby or oneself
• Anxiety or panic that interferes with daily functioning
• Any thoughts of harming oneself or the baby — seek emergency care immediately

If you have a personal or family history of depression, anxiety, or PMDD, tell your care provider before or during pregnancy so proactive monitoring can be arranged. Canadians in provinces with publicly funded midwifery (Ontario, British Columbia, Alberta, and others) can access perinatal mental health screening through their midwife. Virtual care platforms — including Maple, Felix, Cleo, and others — offer remote access to assessment and treatment for those with limited in-person options. PPD is a medical condition, not a character flaw, and it responds well to treatment.

Limitations and open questions

Research is still emerging on several aspects of PPD. The precise biological mechanism linking postpartum hormonal withdrawal to depressive episodes is not fully characterized; not all women with equivalent hormonal drops develop PPD, suggesting individual neurobiological sensitivity that is not yet well understood. The optimal duration of antidepressant treatment after PPD remission — and the point at which tapering is safe — remains an area of active study. Evidence on the long-term neurodevelopmental effects of low-level SSRI exposure through breast milk, while currently reassuring, continues to accumulate. Health Canada has not yet issued specific guidance on brexanolone or zuranolone for PPD, and access to these newer neurosteroid treatments in Canada is limited outside of research settings. Screening rates for paternal PPD in Canadian primary care remain low, and validated tools for non-birthing parents are less well established than the EPDS.